HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY

被引：1
|
作者：
Tavella, F. [1 ]
Korchagina, D. [2 ]
Rodrigues, J. [2 ]
Remuzat, C. [2 ]
机构：
[1] Creativ Ceut, London, England
[2] Creativ Ceut, Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1733
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY103
引用
收藏
页码：A540 / A540
页数：1
相关论文
共 50 条
  • [41] Health Technology Assessment of Vaccines in Italy: History and Review of Applications
    Boccalini, Sara
    Ragusa, Rosalia
    Panatto, Donatella
    Calabro, Giovanna Elisa
    Cortesi, Paolo Angelo
    Giorgianni, Gabriele
    Favaretti, Carlo
    Bonanni, Paolo
    Ricciardi, Walter
    de Waure, Chiara
    VACCINES, 2024, 12 (10)
  • [42] THE PRACTICE OF DECISION-MAKING OF PUBLIC HEALTH AUTHORITIES IN POLAND ON REIMBURSEMENT OF ORPHAN DRUGS
    Skora, K.
    Bochenek, T.
    Augustynska, J.
    Walczak, J.
    VALUE IN HEALTH, 2017, 20 (09) : A564 - A564
  • [43] Health technology assessment in Italy
    Favaretti, Carlo
    Cicchetti, Americo
    Guarrera, Giovanni
    Marchetti, Marco
    Ricciardi, Walter
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 127 - 133
  • [44] Health technology assessment in Italy
    France, G
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2000, 16 (02) : 459 - 474
  • [45] Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
    Paulden, Mike
    Stafinski, Tania
    Menon, Devidas
    McCabe, Christopher
    PHARMACOECONOMICS, 2015, 33 (03) : 255 - 269
  • [46] THE IMPACT OF ACCELERATED REGULATORY APPROVAL ON HEALTH TECHNOLOGY ASSESSMENT: AN EVALUATION OF ORPHAN DRUGS IN FOUR MARKETS
    Gomes, S.
    Jin, G.
    Szende, A.
    Uddin, J.
    VALUE IN HEALTH, 2023, 26 (12) : S352 - S353
  • [47] Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
    Mike Paulden
    Tania Stafinski
    Devidas Menon
    Christopher McCabe
    PharmacoEconomics, 2015, 33 : 255 - 269
  • [48] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [49] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
  • [50] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
12345